Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.

While intensity didn’t appear to matter in this network meta-analysis, location did: in-person programs had the most impact.

These documents have become too technical, too inconsistent, and rely too much on expert opinion, Marco Valgimigli argues.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

Following the recent IDE Approval by the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, this enrolment heralds ...

A study comparing men and women suggests much of the association arises from genetic propensity to both conditions.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

In a field rife with disagreement, STS, AATS, and others say the European guidelines got it right when it comes to CABG.

Greater transparency, monitoring, and regulatory oversight are needed around these transactions, a researcher says.